MX2021002042A - Inhibidores de arginasa y sus metodos de uso. - Google Patents

Inhibidores de arginasa y sus metodos de uso.

Info

Publication number
MX2021002042A
MX2021002042A MX2021002042A MX2021002042A MX2021002042A MX 2021002042 A MX2021002042 A MX 2021002042A MX 2021002042 A MX2021002042 A MX 2021002042A MX 2021002042 A MX2021002042 A MX 2021002042A MX 2021002042 A MX2021002042 A MX 2021002042A
Authority
MX
Mexico
Prior art keywords
methods
arginase inhibitors
boraspiro
dodecan
aza
Prior art date
Application number
MX2021002042A
Other languages
English (en)
Spanish (es)
Inventor
Dedong Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021002042A publication Critical patent/MX2021002042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021002042A 2018-08-22 2019-08-21 Inhibidores de arginasa y sus metodos de uso. MX2021002042A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721113P 2018-08-22 2018-08-22
PCT/EP2019/072341 WO2020038983A1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021002042A true MX2021002042A (es) 2021-04-28

Family

ID=67742403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002042A MX2021002042A (es) 2018-08-22 2019-08-21 Inhibidores de arginasa y sus metodos de uso.

Country Status (25)

Country Link
US (1) US11952392B2 (enExample)
EP (2) EP4371614A3 (enExample)
JP (1) JP7441210B2 (enExample)
KR (1) KR102668252B1 (enExample)
CN (1) CN112584900B (enExample)
AU (1) AU2019323663B2 (enExample)
CA (1) CA3109100A1 (enExample)
CL (1) CL2021000430A1 (enExample)
DK (1) DK3840837T3 (enExample)
EA (1) EA202190532A1 (enExample)
ES (1) ES2980252T3 (enExample)
FI (1) FI3840837T3 (enExample)
HR (1) HRP20240694T1 (enExample)
HU (1) HUE066903T2 (enExample)
IL (1) IL280924B2 (enExample)
LT (1) LT3840837T (enExample)
MA (1) MA53427B1 (enExample)
MX (1) MX2021002042A (enExample)
PL (1) PL3840837T3 (enExample)
PT (1) PT3840837T (enExample)
RS (1) RS65608B1 (enExample)
SG (1) SG11202101618PA (enExample)
SI (1) SI3840837T1 (enExample)
SM (1) SMT202400221T1 (enExample)
WO (1) WO2020038983A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MY206577A (en) * 2019-02-08 2024-12-24 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP4239652A4 (en) 2020-12-25 2024-06-05 Sumitomo Riko Company Limited Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3840837B1 (en) 2024-03-20
SMT202400221T1 (it) 2024-07-09
JP7441210B2 (ja) 2024-02-29
CA3109100A1 (en) 2020-02-27
EP4371614A2 (en) 2024-05-22
KR102668252B1 (ko) 2024-05-21
US20210332068A1 (en) 2021-10-28
PL3840837T3 (pl) 2024-08-19
MA53427B1 (fr) 2024-06-28
WO2020038983A1 (en) 2020-02-27
HRP20240694T1 (hr) 2024-08-16
KR20210049120A (ko) 2021-05-04
US11952392B2 (en) 2024-04-09
RS65608B1 (sr) 2024-07-31
CN112584900B (zh) 2025-07-15
IL280924B2 (en) 2024-10-01
HUE066903T2 (hu) 2024-09-28
IL280924B1 (en) 2024-06-01
SI3840837T1 (sl) 2024-07-31
EP3840837A1 (en) 2021-06-30
MA53427A (fr) 2021-12-01
DK3840837T3 (da) 2024-06-10
JP2021535111A (ja) 2021-12-16
EA202190532A1 (ru) 2021-07-08
AU2019323663B2 (en) 2022-07-14
IL280924A (en) 2021-04-29
SG11202101618PA (en) 2021-03-30
ES2980252T3 (es) 2024-09-30
LT3840837T (lt) 2024-06-10
AU2019323663A1 (en) 2021-04-08
FI3840837T3 (fi) 2024-06-03
EP4371614A3 (en) 2025-09-24
CL2021000430A1 (es) 2021-09-03
PT3840837T (pt) 2024-06-14
CN112584900A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
PH12022551379A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
GEAP202415928A (en) Pyridine oxynitride, preparation method therefor and use thereof
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
EA202190532A1 (ru) Ингибиторы аргиназы и способы их применения
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EA033689B9 (ru) Ингибиторы g12c kras
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
CR20240514A (es) Compuestos de heteroarilo para el tratamiento del dolor
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MY169432A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX372773B (es) Ácido (2s, 4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico.
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2022006331A3 (en) Pyridine-1,5-diones exhibitng mnk inhibition and their method of use
MY191183A (en) (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.